Columbia-based Advarra, which operates in the regulatory review solutions, research quality and compliance consulting services, and clinical site-centric technologies spaces, has acquired Bio-Optronics, maker of CCTrialSuite – which includes Clinical Conductor, the leading clinical trial management system (CTMS) for health systems and research sites and an integrated suite of eClinical solutions.

The acquisition, in combination with Advarra’s existing suite of products and services, establishes Advarra as a site technology market leader with extensive reach, customer loyalty and the highest standards of customer support to the 50,000 investigators whose sites run on Advarra software.

With the acquisition of Bio-Optronics, Advarra builds on its established relationships with academic medical centers, cancer centers and sites through its OnCore CTMS to now include a broader coverage of site networks and health systems of any size, as well as commercial sites supported by CCTrialSuite. Additionally, the acquisition enhances Advarra’s commitment to clinical research and furthers Advarra’s objective to connect the clinical trial ecosystem – sponsors, clinical research organizations (CROs) and sites – to make clinical research safer, smarter and faster.

Clinical trial sites can range from research centers, academic medical centers to hospitals and health systems, private practices and broader site networks. Regardless of type, sites rely on clinical trial management technology to improve the efficiency and effectiveness of clinical research, improve trial recruitment, protocol adherence, financial management and compliance and to provide greater visibility for sponsoring organizations, CROs and regulatory bodies.

“The addition of CCTrialSuite and Bio-Optronics’ global customer base enhances Advarra’s technology portfolio and further solidifies our position as the de facto standard for clinical research site technology,” said Advarra CEO Gadi Saarony. “Additionally, the acquisition further strengthens our ability to enable sites with technology and services built for their unique needs and connect them to CROs and sponsor organizations in the clinical trial ecosystem to accelerate the advancement of human health.”